Omega Therapeutics Inc. (OMGA)
0.59
-0.04 (-5.78%)
At close: Jan 14, 2025, 3:59 PM
undefined% (undefined)
| Bid | 0.64 |
| Market Cap | 32.83M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.66 |
| Volume | 227,067 |
| Avg. Volume (20D) | 340,708 |
| Open | 0.65 |
| Previous Close | 0.63 |
| Day's Range | 0.58 - 0.66 |
| 52-Week Range | 0.58 - 4.46 |
| Beta | undefined |
About OMGA
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore live...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 93
Stock Exchange NASDAQ
Ticker Symbol OMGA
Analyst Forecast
According to 5 analyst ratings, the average rating for OMGA stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1923.61% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Omega Therapeutics Inc. is scheduled to release its earnings on Mar 27, 2025,
before market opens.
Analysts project revenue of $1.24M, reflecting a 25.38% YoY growth and earnings per share of -0.22, making a -40.54% decrease YoY.
Analysts project revenue of $1.24M, reflecting a 25.38% YoY growth and earnings per share of -0.22, making a -40.54% decrease YoY.
2 months ago ·
Source
-17.98%
Omega Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
7 months ago ·
Source
+19.35%
Omega Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with an Outperform rating and announced a $12 price target.
